UNSPSC 51272110: Tolycaine

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12R8659YM6. European Medicines Agency schedules Tolycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11183MIG. Tolycaine generally arises in the molecular formula C15H22N2O3.

The term TOLYCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) TOLYCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolycaine under HS 29242995 and SITC 51479. As of Q4 2014, TOLYCAINE remains the US FDA Preferred Term for this commodity. Tolycaine bears US NLM identifiers UMLS ID C0538453 and NCI Concept Code C75105. SMILES: O=C(NC1C(CCCC1C(=O)OC)C)CN(CC)CC.

UNSPSC 51272110 Tolycaine, a Commodity code, does not align with the state and local procurement activity tagged under it. The recent opportunities in the source involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—none of which are tolycaine-specific products. The code shows little relevant recent activity for tolycaine itself; the mismatch suggests either a cataloging error in how opportunities are tagged or that state and local governments are not actively procuring tolycaine under this code at present.

The three opportunities on record involve different issuing bodies and procurement mechanisms. Seminole County, Florida posted an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), with quarterly deliveries to the Seminole County Community Health Building and vendor responsibility for all shipping costs. The Texas Health and Human Services Commission issued a Request for Information on a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program (posted April 3, 2026) to gather market intelligence on vendor capacity to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with products required to be available by May 15, 2026 and contract effectiveness July 1, 2026. Activity appears concentrated in the Southeast and Midwest; without direct relevance to tolycaine procurement, the code does not present a clear acquisition pathway under its nominal scope.